Pantop%25252520ds

# Pantoprazole (Pantop DS) ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells. "DS" often refers to Double Strength (typically 40 mg). ## Primary Indications * Erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Prophylaxis of stress-induced upper GI hemorrhage (ICU setting). ## Adult Dosing * **GERD/Erosive Esophagitis:** 40 mg PO or IV once daily for 8 weeks; may continue for another 8 weeks if necessary. * **Maintenance of Healing:** 40 mg PO daily. * **Hypersecretory Conditions:** Starting dose 40 mg PO BID; may titrate up to 240 mg/day based on patient needs. * **Stress Ulcer Prophylaxis:** 40 mg IV daily. ## Pediatric Dosing * **GERD (≥ 5 years old):** * 15 kg to < 40 kg: 20 mg once daily for up to 8 weeks. * ≥ 40 kg: 40 mg once daily for up to 8 weeks. * *Note: Safety and efficacy for other pediatric conditions or younger ages are not universally established.* ## Dose Adjustments * **Hepatic Impairment:** No specific dose adjustment defined for mild-to-moderate impairment, but clinical monitoring is advised for severe impairment. * **Renal Impairment:** No dosage adjustment indicated. * *Note: Always consult local institutional protocols for severe hepatic or renal dysfunction.* ## Contraindications * Hypersensitivity to pantoprazole or any component of the formulation. * Concurrent use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence. * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus. ## Key Drug Interactions * **pH-dependent drugs:** May decrease absorption of ketoconazole, atazanavir, and certain iron salts. * **Methotrexate:** PPIs may increase serum levels of methotrexate (monitor closely). * **Warfarin:** Monitor INR frequently as PPIs may alter metabolism in some patients. ## Monitoring * **Long-term use:** Monitor serum magnesium levels periodically. * **Clinical:** Monitor for signs of *C. difficile* infection (unresolved diarrhea) and signs of B12 deficiency. * **Renal:** Monitor for worsening renal function if interstitial nephritis is suspected. ## Clinical Pearls * **Administration:** Tablets should be swallowed whole; do not crush or chew. IV administration should be a 15-minute infusion or a 2-minute slow bolus (varies by local protocol). * **Duration:** Use the lowest effective dose for the shortest duration necessary to minimize risk of side effects. * **Tapering:** Long-term users may experience rebound acid hypersecretion upon discontinuation; consider tapering. *** **Educational Disclaimer:** This information is for educational purposes only. Always verify drug dosages, contraindications, and clinical protocols against current local prescribing information, institutional guidelines, and official product monographs before administering medication.